Tilray (TLRY) AI Stock Analysis

• Market Cap: $1.62B
• Dividend Yield: N/A
• Average Volume (3M): 11.35M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: 2.31%
• EPS Growth: -726.28%
• Country: US
• Employees: 2,650
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 116,000,000
• 10 Day Avg. Volume: 24,644,109
• 30 Day Avg. Volume: 11,350,191
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.18
• Price to Sales (P/S): 0.34
• P/FCF Ratio: -2.17
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 1.23
• Enterprise Value/Gross Profit: 4.30
• Enterprise Value/Ebitda: -0.48
• 1Y Price Target: $7.00
• Price Target Upside: 442.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $12.00 ▲(830.23% Upside)

Tilray's overall stock score is primarily impacted by its weak financial performance, with significant losses and liquidity issues. While the earnings call provided some positive insights into revenue growth and strategic initiatives, the valuation remains a concern due to the negative P/E ratio. Technical analysis indicates some volatility, but no clear trend. The company's ability to address profitability and cash generation will be crucial for future improvement.

Positive Factors

Regulatory Changes

Reclassification of marijuana to a less regulated schedule could enhance market opportunities and reduce tax burdens, supporting long-term growth.

International Expansion

Growth in international markets, especially in Germany, indicates successful expansion strategies, potentially increasing global market share.

Product Innovation

Introducing new products like the Amped Live Resin line can drive consumer interest and revenue, enhancing competitive positioning in the cannabis market.

Negative Factors

Cash Flow Issues

Persistent negative cash flows indicate liquidity challenges, potentially limiting the company's ability to invest in growth and manage operations effectively.

Profitability Concerns

Significant losses and negative profit margins suggest ongoing struggles with profitability, which could hinder long-term financial health and investor confidence.

Permitting Delays

Permitting delays in key markets like Portugal can disrupt international operations and growth plans, impacting revenue and strategic objectives.

Tilray Business Overview & Revenue Model

Company Description

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.

How the Company Makes Money

Tilray generates revenue primarily through the sale of cannabis products in both the medical and recreational markets. Key revenue streams include direct-to-consumer sales through its own distribution channels and partnerships with licensed retailers. The company also engages in wholesale distribution to other cannabis companies and dispensaries. Additionally, Tilray has been expanding its presence in the global market by entering into strategic partnerships and joint ventures, such as collaborations with major alcohol brands and pharmaceutical companies, which provide further avenues for revenue generation. The company's investments in research and development of innovative products and its focus on international expansion are also significant contributors to its earnings.

Tilray Financial Statement Overview

Summary

Tilray's financial performance is weak, with significant losses and declining revenue growth. The income statement shows a deeply negative net profit margin, and cash flow analysis reveals liquidity issues with negative cash flows. The balance sheet indicates low leverage but ongoing profitability concerns.

Income Statement

Tilray's income statement reveals significant challenges, with negative net profit margins and declining revenue growth. The TTM data shows a gross profit margin of 28.77%, but the net profit margin is deeply negative at -278.12%, indicating substantial losses. Revenue growth is negative, suggesting a contraction in sales. Overall, the company is struggling with profitability and growth.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.15 in the TTM period, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not provided, but the available data suggests financial stability in terms of debt management, albeit with profitability concerns.

Cash Flow

Cash flow analysis highlights significant issues, with negative operating and free cash flows. The TTM data shows a free cash flow growth rate of -31.63%, indicating worsening cash generation. The operating cash flow to net income ratio is negative, reflecting poor cash conversion. Overall, the cash flow situation is concerning, with limited liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.16B	1.13B	1.07B	844.72M	792.12M	619.67M
Gross Profit	332.50M	330.11M	304.33M	197.95M	147.26M	148.77M
EBITDA	-2.96B	-2.92B	-99.25M	-1.72B	-310.61M	-297.41M
Net Income	-3.01B	-3.00B	-333.80M	-1.96B	-601.05M	-443.75M
Balance Sheet
Total Assets	2.08B	2.90B	5.91B	5.92B	6.87B	6.03B
Cash, Cash Equivalents and Short-Term Investments	264.83M	351.78M	354.98M	604.16M	524.29M	488.47M
Total Debt	231.29M	451.09M	527.75M	794.89M	786.36M	938.66M
Total Liabilities	561.99M	860.49M	1.22B	1.44B	1.27B	1.56B
Stockholders Equity	1.54B	2.07B	4.69B	4.47B	5.55B	4.46B
Cash Flow
Free Cash Flow	-119.70M	-174.98M	-81.96M	-17.37M	-266.39M	-100.93M
Operating Cash Flow	-83.01M	-129.81M	-42.11M	10.65M	-223.45M	-53.99M
Investing Cash Flow	28.48M	-64.11M	174.88M	-384.04M	-27.14M	55.67M
Financing Cash Flow	120.54M	183.20M	-102.45M	94.50M	161.60M	150.09M

Tilray Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLRY, the sentiment is Positive. The current price of 1.29 is below the 20-day moving average (MA) of 9.37, below the 50-day MA of 12.06, and below the 200-day MA of 8.56, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 57.79 is Neutral, neither overbought nor oversold. The STOCH value of 76.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TLRY.

Tilray Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRON	67 Neutral	C$1.60B	31.12	3.34%	―	22.20%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDL	48 Neutral	$533.02M	-8.11	-7.82%	―	1.76%	18.31%
TLRY	47 Neutral	$1.62B	―	-85.59%	―	2.31%	-726.28%
IMCC	45 Neutral	$9.23M	-1.93	-93.87%	―	-0.74%	81.49%
HYFM	44 Neutral	$10.31M	-0.14	-30.93%	―	-26.84%	-0.16%
EVGN	43 Neutral	$8.80M	-2.01	―	―	-29.78%	88.96%

Tilray Corporate Events

Tilray Announces Reverse Stock Split Effective December 1

Tilray Brands announced the implementation of a one-for-ten reverse stock split of its common stock, effective December 1, 2025, with trading on a split-adjusted basis starting December 2, 2025. This move aims to align the number of shares with companies of similar size, attract institutional shareholders, and reduce costs associated with its Annual Meeting of Stockholders, potentially saving up to $1 million annually. The reverse stock split will reduce the number of outstanding shares from approximately 1.16 billion to 116 million, with no fractional shares issued, maintaining stockholders’ proportional ownership.

Tilray Stockholders Meeting Approves Key Proposals

On November 18, 2025, Tilray Brands, Inc. held its annual stockholders meeting where several key proposals were voted on. The re-election of John Herhalt as Class I director and the ratification of PricewaterhouseCoopers LLP as the independent accounting firm were approved. However, the proposal to amend the company’s governance structure to declassify the board and change director removal provisions did not pass, indicating mixed support for governance changes among stockholders.

Tilray Releases Investor Presentation November 2025

Tilray Brands, Inc. has released an investor presentation on November 17, 2025, which is available on their website. The presentation is provided for informational purposes and is not intended to be filed under the Securities and Exchange Act of 1934.